re: AMRN anyone?

So their big product is Vascepa. Their stock had two big drops after they lost a patent lawsuit and subsequent appeal against generic drug manufacturers who are also vying to produce the drug.

What I have also gathered is that the generic drug makers are unable to produce Vascepa at a lower cost of production as Amarin. As a result Amarin has not lost market share. And if the drug is as promising as it sounds they could have monster sales.All of this is hearsay and I don’t have any hard numbers, but if their next earnings report shows great sales numbers then it will be proven true.

I’ve flipped a few times. They are currently back at pre-drop prices, so there might be some overhead resistance. However, if they break through the resistance it’ll probably go to the teens

For me the stock gives me the same vibe as stamps.com which had two really big drops in price, got their shite together, and then shot to the moon.